Search Results - "Farah, Jareer O"

Conivaptan and its role in the treatment of hyponatremia by Ghali, Jalal K, Farah, Jareer O, Daifallah, Suleiman, Zabalawi, Hassan A, Zmily, Hammam D

“…Hyponatremia is the most common electrolyte abnormality in hospitalized patients and is associated with increased morbidity and mortality. The recognition of…”
Get full text

Anemia in a Predominantly African American Population With Heart Failure by Zmily, Hammam D, Farah, Jareer O, Mohammed, Mohammed, Ali, Azzat, Tam, S. William, Levy, Phillip, Ghali, Jalal K

Get full text

FACTORS LEADING TO 30 DAY READMISSION FOLLOWING HOSPITALIZATION FOR HEART FAILURE by Ghali, Jalal K, Zmily, Hammam D, Shaik, Ibrahim, Farah, Jareer O, Daifallah, Suleiman, Kaur, Ramanjit, Ali, Omaima A, Samarah, Husam Al, Levy, Phillip, Tam, S. William, Schreiber, Michelle

Get full text

CHARACTERISTICS OF PATIENTS REHOSPITALIZED WITH ACUTE DECOMPENSATED HEART FAILURE (ADHF) WITHIN 30 DAYS FOLLOWING DISCHARGE by Zalawadiya, Sandip K, Zmily, Hammam D, Farah, Jareer O, Daifallah, Suleiman, Ali, Omaima A, Ghali, Jalal K

Get full text

Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia by Ghali, Jalal K, Zmily, Hammam D, Farah, Jareer O, Daifallah, Suleiman

“…Lixivaptan (VPA-985), being developed by Biogen Idec and Cardiokine, under license from Wyeth (now part of Pfizer), is a non-peptide, selective vasopressin V2…”
Get more information